NCT01699711View on ClinicalTrials.gov

Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

March 31, 2015

Conditions
Down Syndrome (DS)
Interventions
DIETARY_SUPPLEMENT

Epigallocatechin-3-gallate (EGCG)

EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.

Trial Locations (1)

08003

IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona

All Listed Sponsors
lead

Parc de Salut Mar

OTHER

NCT01699711 - Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool | Biotech Hunter | Biotech Hunter